Agents targeting prostate cancer bone metastasis

Khalid S. Mohammad, Pierrick G. Fournier, Theresa A. Guise, John M. Chirgwin

Research output: Contribution to journalReview article

5 Scopus citations


Bone is the most common site for metastasis of advanced prostate cancers. Once housed in the skeleton, tumors are incurable and cause protracted morbidity, and bone metastases may contribute to mortality through unknown mechanisms. Bone provides a unique microenvironment whose local interactions with tumor cells offer novel targets for therapeutic interventions. Many standard cancer treatments cause bone loss, which may aggravate skeletal metastases, although this is preventable with approved agents. Improved bone-targeted treatments can decrease the serious skeletal morbidities associated with metastatic prostate cancer and may in the future improve overall survival. The development of such treatments requires preclinical evaluation in animal models of prostate cancer growth in bone.

Original languageEnglish (US)
Pages (from-to)1079-1088
Number of pages10
JournalAnti-Cancer Agents in Medicinal Chemistry
Issue number10
StatePublished - Jan 1 2009


  • Bisphosphonate
  • Bone
  • Endothelin
  • Metastasis
  • Osteoblastic
  • Osteolytic
  • Prostate cancer
  • RANK ligand
  • TGF-beta

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Medicine
  • Pharmacology
  • Medicine(all)

Fingerprint Dive into the research topics of 'Agents targeting prostate cancer bone metastasis'. Together they form a unique fingerprint.

  • Cite this